Company profile

Avelo AG

Avelo develops a breath collector to improve the diagnosis of Tuberculosis and respiratory infections causing pneumonia, the world’s 4th leading cause of death. Doctors use this non-invasive sampling tool to painlessly collect a patient’s breath sample from the respiratory tract and analyze it with existing PCR tests for fast and accurate diagnosis. This improves patient outcomes, saves healthcare costs, and avoids unnecessary prescription of antibiotics. Avelo invented the breath collector with broad utility in mind, comparable to other sample collection technologies such as blood tubes (6bn market potential).

More news about Avelo AG

21.03.2024 12:15

Drei Deeptech-Startups im Finale um den ZKB Pionierpreis Technopark

Please login or
register to use the
awards follow feature
25.01.2024 14:35

ZKB Pionierpreis Technopark shortlists 11 startups

Please login or
register to use the
awards follow feature
29.11.2023 17:00

Swiss Delegation to Helsinki to demonstrate their innovation prowess

Please login or
register to use the
awards follow feature
27.11.2023 16:00

European grants fuel the development of new solutions

Please login or
register to use the
awards follow feature
12.12.2022 16:00

IMD Startup Competition reveals the 2022/2023 winners

Please login or
register to use the
awards follow feature
20.09.2022 13:03

Avelo closes CHF 2.2 million oversubscribed seed round

Please login or
register to use the
awards follow feature
22.06.2022 16:50

Avelo wins CHF 150,000 to improve respiratory disease diagnoses

Please login or
register to use the
awards follow feature
Avelo AG

Founded
2020

Kanton
ZH


LinkedIn

Homepage

rss